A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether lung volume reduction surgery (LVRS) might be superior to medical treatment in the management of patients with severe emphysema. Overall 497 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that LVRS produces superior patient outcomes compared to medical treatment in terms of exercise capacity, lung function, quality of life and long-term ()1 year postoperative) survival. A large proportion of the best evidence on this topic is based on analysis of the National Emphysema Treatment Trial (NETT). Seven studies compared LVRS to medical treatment alone (MTA) using data generated by the NETT trial. They found higher quality of life scores (45.3 vs. 27.5, P-0.001), improved maximum ventilation (32.8 vs. 29.6 lymin, Ps0.001) and lower exacerbation rate per person-year (0.27 vs. 0.37%, Ps0.0005) with LVRS than MTA. Mortality rates for LVRS were greater up to one year (Ps0.01), equivalent by three years (Ps0.15) and lower after four years (Ps0.06) postoperative compared to MTA. Patients with upper-lobe-predominant disease and low exercise capacity (0.36 vs. 0.54, Ps0.003) benefited the most from undergoing LVRS rather than MTA in terms of probability of death at five years compared to patients with non-upper-lobe disease (0.38 vs. 0.45, Ps0.03) or upper-lobedisease with high exercise capacity (0.33 vs. 0.38, Ps0.32). Five studies compared LVRS to MTA using data independent from the NETT trial. They found greater six-minute walking distances (433 vs. 300 m, P-0.002), improved total lung capacity (18.8 vs. 7.9% predicted, P-0.02) and quality of life scores (47 vs. 23.2, P-0.05) with LVRS compared to MTA. Even though LVRS has a much greater cost per person over five years ($137,000 vs. $100,200, P-0.001), its improved lung function, greater exercise capacity and better quality of life scores make it a preferable treatment option to MTA, with particular indications for patients with upper-lobe-predominant disease and low exercise capacity.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients with severe emphysemax is wLung Volume Reduction Surgeryx superior to wmedical treatmentx in terms of wsurvival, lung function and quality of lifex.
Clinical scenario
You see a 65-year-old male with heterogeneous, upperlobe-predominant emphysema identified on computed tomography (CT). Over the past six months, he has become more short of breath despite complying with his medication and completing eight weeks of pulmonary rehabilitation. *Corresponding author. Tel.yfax: q44 751 5542899. E-mail address: marco.scarci@mac.com (M. Scarci).
He complains that he is finding it progressively more difficult to walk short distances. You feel that lung volume reduction surgery (LVRS) may provide a better quality of life and improve exercise capacity than just continued medication use. You carry out a review of the literature.
Search strategy
Medline search 2000 to October 2010 was performed using the OVID interface wLVRS.mp OR Lung volume reduction.mpx AND wCOPD.mp OR exp pulmonary disease, Chronic ObstructiveyEmphysema.mp or exp Emphysemayx AND wsurgery.mpx.
Search outcome
Four hundred and ninety-seven papers were found using the reported search. From these 12 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
In addition, the reference list of each paper was searched. 
Results
Seven studies compared LVRS to medical treatment alone (MTA) using data generated by the National Emphysema Treatment Trial ( 
Clinical bottom line
Lung volume reduction is becoming increasingly recognised as an effective treatment option for severe emphysema. Currently, no consensus is in place on which patients should be considered for surgery. The studies above have shown that LVRS improves lung function, exercise capacity and quality of life more than conservative treatment with additional benefits for patients with upper-lobe-predominant disease and low exercise capacity. However, its greater cost and higher peri-treatment mortality rates assert caution to its use in patients with multiple co-morbidities or homogenous disease.
